Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin target attainment during neutropenia prophylaxis in hematologic malignancies
NL-OMON48253Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ciprofloxacin in chemotherapy-induced neutropenia (CIN) and hematopoietic malignancies, sponsored by Amsterdam University Medical Center. Primary endpoint: PK/PD target attainment defined as AUC0-24/MIC >= 125. Started Mar 2019; status: active, not recruiting.
02
Drugs
ciprofloxacin
03
Conditions
chemotherapy-induced neutropenia (CIN)hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON48253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48253.